AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy
In five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patients undergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3 provoked significant decreases in the incidence of bon...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/917546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564440897159168 |
|---|---|
| author | Vicente G Villarrubia Paula Marquez Jose Cobo Guillermo J Sada |
| author_facet | Vicente G Villarrubia Paula Marquez Jose Cobo Guillermo J Sada |
| author_sort | Vicente G Villarrubia |
| collection | DOAJ |
| description | In five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patients
undergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3
provoked significant decreases in the incidence of bone-marrow hypoplasia (20.5% versus 61.1%). This
marrow effect was also manifested in peripheral blood by higher levels of white blood cells, mononuclear
cells and platelets in the AM3 treated group. The incidence of thrombocytopenia in patients receiving
combined radio-chemotherapy only was 70% compared with 6% observed in patients also receiving AM3
treatment. Besides these hematological effects, AM3 palliated subclinical hepatic toxicity due to combined
radio-chemotherapy. Finally, studies on acute-phase reactants, such as C-reactive protein, IgA. and factors
B, C'3, and C'5 of the complement system, suggest that a modulation of hepatic inflammatory responses
by AM3 appears to be essential for clinical effects described. |
| format | Article |
| id | doaj-art-ef33a1df8d194177812113cda1d0c109 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-ef33a1df8d194177812113cda1d0c1092025-02-03T01:11:04ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-013Suppl B13814210.1155/1992/917546AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant RadiochemotherapyVicente G VillarrubiaPaula MarquezJose CoboGuillermo J SadaIn five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patients undergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3 provoked significant decreases in the incidence of bone-marrow hypoplasia (20.5% versus 61.1%). This marrow effect was also manifested in peripheral blood by higher levels of white blood cells, mononuclear cells and platelets in the AM3 treated group. The incidence of thrombocytopenia in patients receiving combined radio-chemotherapy only was 70% compared with 6% observed in patients also receiving AM3 treatment. Besides these hematological effects, AM3 palliated subclinical hepatic toxicity due to combined radio-chemotherapy. Finally, studies on acute-phase reactants, such as C-reactive protein, IgA. and factors B, C'3, and C'5 of the complement system, suggest that a modulation of hepatic inflammatory responses by AM3 appears to be essential for clinical effects described.http://dx.doi.org/10.1155/1992/917546 |
| spellingShingle | Vicente G Villarrubia Paula Marquez Jose Cobo Guillermo J Sada AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy Canadian Journal of Infectious Diseases |
| title | AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy |
| title_full | AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy |
| title_fullStr | AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy |
| title_full_unstemmed | AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy |
| title_short | AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy |
| title_sort | am3 an oral brm protective agent against iatrogenic bone marrow and liver damage in breast cancer patients under conventional adjuvant radiochemotherapy |
| url | http://dx.doi.org/10.1155/1992/917546 |
| work_keys_str_mv | AT vicentegvillarrubia am3anoralbrmprotectiveagentagainstiatrogenicbonemarrowandliverdamageinbreastcancerpatientsunderconventionaladjuvantradiochemotherapy AT paulamarquez am3anoralbrmprotectiveagentagainstiatrogenicbonemarrowandliverdamageinbreastcancerpatientsunderconventionaladjuvantradiochemotherapy AT josecobo am3anoralbrmprotectiveagentagainstiatrogenicbonemarrowandliverdamageinbreastcancerpatientsunderconventionaladjuvantradiochemotherapy AT guillermojsada am3anoralbrmprotectiveagentagainstiatrogenicbonemarrowandliverdamageinbreastcancerpatientsunderconventionaladjuvantradiochemotherapy |